Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases

Alfred Balasa, Grace Gathungu, P. Kisfali, E. O'Brian Smith, Judy H. Cho, B. Melegh, Richard Kellermayer

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and aims: A 5-bp insertion-deletion (indel) polymorphism in the promoter of interferon regulatory factor 5 (IRF5) has been associated with inflammatory bowel diseases (IBD). This polymorphism generates an additional binding site for the transcription factor SP1 and has been shown to augment the expression of IRF5. Additionally, it affects a CpG dinucleotide-dense genomic region. These features of the indel suggested that it may influence the epigenetic regulation of IRF5. The aim of this study was to investigate the potential effect of the 5-bp indel on the methylation pattern of four CpG sites upstream of the polymorphism. Possible CpG site methylation differences in this region between healthy persons and individuals suffering from IBD were also tested. Methods: Genotype was determined by 4% polyacrylamide gel electrophoresis in 33 peripheral blood leukocyte (PBL) DNA samples. DNA methylation correlates of the genotypes were measured by bisulfite pyrosequencing. IRF5 promoter methylation in association to disease state was assessed in 87 proband (49 healthy, 18 Crohn's disease, 20 ulcerative colitis) PBL samples. Results: The polymorphism did not affect the methylation pattern of the IRF5 promoter nor could we detect significant differences in the average, low methylation of the locus between healthy persons and individuals with IBD. Conclusions: These results implicate that epigenetic dysregulation of the IRF5 promoter is unlikely to be associated with IBD.

Original languageEnglish
Pages (from-to)553-556
Number of pages4
JournalInternational Journal of Colorectal Disease
Volume25
Issue number5
DOIs
Publication statusPublished - May 2010

Fingerprint

Interferon Regulatory Factors
DNA Methylation
Inflammatory Bowel Diseases
Genetic Promoter Regions
Methylation
Epigenomics
Leukocytes
Genotype
Ulcerative Colitis
Crohn Disease
Polyacrylamide Gel Electrophoresis
Transcription Factors
Binding Sites
DNA

Keywords

  • DNA methylation
  • Inflammatory bowel diseases
  • IRF5
  • Polymorphism

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases. / Balasa, Alfred; Gathungu, Grace; Kisfali, P.; O'Brian Smith, E.; Cho, Judy H.; Melegh, B.; Kellermayer, Richard.

In: International Journal of Colorectal Disease, Vol. 25, No. 5, 05.2010, p. 553-556.

Research output: Contribution to journalArticle

Balasa, Alfred ; Gathungu, Grace ; Kisfali, P. ; O'Brian Smith, E. ; Cho, Judy H. ; Melegh, B. ; Kellermayer, Richard. / Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases. In: International Journal of Colorectal Disease. 2010 ; Vol. 25, No. 5. pp. 553-556.
@article{45ec7f6c108543db9f0b0fb82902273d,
title = "Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases",
abstract = "Background and aims: A 5-bp insertion-deletion (indel) polymorphism in the promoter of interferon regulatory factor 5 (IRF5) has been associated with inflammatory bowel diseases (IBD). This polymorphism generates an additional binding site for the transcription factor SP1 and has been shown to augment the expression of IRF5. Additionally, it affects a CpG dinucleotide-dense genomic region. These features of the indel suggested that it may influence the epigenetic regulation of IRF5. The aim of this study was to investigate the potential effect of the 5-bp indel on the methylation pattern of four CpG sites upstream of the polymorphism. Possible CpG site methylation differences in this region between healthy persons and individuals suffering from IBD were also tested. Methods: Genotype was determined by 4{\%} polyacrylamide gel electrophoresis in 33 peripheral blood leukocyte (PBL) DNA samples. DNA methylation correlates of the genotypes were measured by bisulfite pyrosequencing. IRF5 promoter methylation in association to disease state was assessed in 87 proband (49 healthy, 18 Crohn's disease, 20 ulcerative colitis) PBL samples. Results: The polymorphism did not affect the methylation pattern of the IRF5 promoter nor could we detect significant differences in the average, low methylation of the locus between healthy persons and individuals with IBD. Conclusions: These results implicate that epigenetic dysregulation of the IRF5 promoter is unlikely to be associated with IBD.",
keywords = "DNA methylation, Inflammatory bowel diseases, IRF5, Polymorphism",
author = "Alfred Balasa and Grace Gathungu and P. Kisfali and {O'Brian Smith}, E. and Cho, {Judy H.} and B. Melegh and Richard Kellermayer",
year = "2010",
month = "5",
doi = "10.1007/s00384-010-0874-0",
language = "English",
volume = "25",
pages = "553--556",
journal = "International Journal of Colorectal Disease",
issn = "0179-1958",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases

AU - Balasa, Alfred

AU - Gathungu, Grace

AU - Kisfali, P.

AU - O'Brian Smith, E.

AU - Cho, Judy H.

AU - Melegh, B.

AU - Kellermayer, Richard

PY - 2010/5

Y1 - 2010/5

N2 - Background and aims: A 5-bp insertion-deletion (indel) polymorphism in the promoter of interferon regulatory factor 5 (IRF5) has been associated with inflammatory bowel diseases (IBD). This polymorphism generates an additional binding site for the transcription factor SP1 and has been shown to augment the expression of IRF5. Additionally, it affects a CpG dinucleotide-dense genomic region. These features of the indel suggested that it may influence the epigenetic regulation of IRF5. The aim of this study was to investigate the potential effect of the 5-bp indel on the methylation pattern of four CpG sites upstream of the polymorphism. Possible CpG site methylation differences in this region between healthy persons and individuals suffering from IBD were also tested. Methods: Genotype was determined by 4% polyacrylamide gel electrophoresis in 33 peripheral blood leukocyte (PBL) DNA samples. DNA methylation correlates of the genotypes were measured by bisulfite pyrosequencing. IRF5 promoter methylation in association to disease state was assessed in 87 proband (49 healthy, 18 Crohn's disease, 20 ulcerative colitis) PBL samples. Results: The polymorphism did not affect the methylation pattern of the IRF5 promoter nor could we detect significant differences in the average, low methylation of the locus between healthy persons and individuals with IBD. Conclusions: These results implicate that epigenetic dysregulation of the IRF5 promoter is unlikely to be associated with IBD.

AB - Background and aims: A 5-bp insertion-deletion (indel) polymorphism in the promoter of interferon regulatory factor 5 (IRF5) has been associated with inflammatory bowel diseases (IBD). This polymorphism generates an additional binding site for the transcription factor SP1 and has been shown to augment the expression of IRF5. Additionally, it affects a CpG dinucleotide-dense genomic region. These features of the indel suggested that it may influence the epigenetic regulation of IRF5. The aim of this study was to investigate the potential effect of the 5-bp indel on the methylation pattern of four CpG sites upstream of the polymorphism. Possible CpG site methylation differences in this region between healthy persons and individuals suffering from IBD were also tested. Methods: Genotype was determined by 4% polyacrylamide gel electrophoresis in 33 peripheral blood leukocyte (PBL) DNA samples. DNA methylation correlates of the genotypes were measured by bisulfite pyrosequencing. IRF5 promoter methylation in association to disease state was assessed in 87 proband (49 healthy, 18 Crohn's disease, 20 ulcerative colitis) PBL samples. Results: The polymorphism did not affect the methylation pattern of the IRF5 promoter nor could we detect significant differences in the average, low methylation of the locus between healthy persons and individuals with IBD. Conclusions: These results implicate that epigenetic dysregulation of the IRF5 promoter is unlikely to be associated with IBD.

KW - DNA methylation

KW - Inflammatory bowel diseases

KW - IRF5

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=77953290791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953290791&partnerID=8YFLogxK

U2 - 10.1007/s00384-010-0874-0

DO - 10.1007/s00384-010-0874-0

M3 - Article

C2 - 20127100

AN - SCOPUS:77953290791

VL - 25

SP - 553

EP - 556

JO - International Journal of Colorectal Disease

JF - International Journal of Colorectal Disease

SN - 0179-1958

IS - 5

ER -